Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology May 19, 2022
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference May 17, 2022
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results May 10, 2022
There are currently no events to display.
Developing novel therapeutics for the treatment of rare diseases.